Skip to main content
Optipharm.CO.,LTD logo

Optipharm.CO.,LTD — Investor Relations & Filings

Ticker · 153710 ISIN · KR7153710009 KO Professional, scientific and technical activities
Open in API
Filings indexed 177 across all filing types
Latest filing 2024-03-08 AGM Information
Country KR South Korea
Listing KO 153710

About Optipharm.CO.,LTD

https://www.optipharm.co.kr

Optipharm is a biomedical company specializing in animal health solutions and advanced biotherapeutics. The company's core activities encompass animal disease diagnosis, the development and sale of veterinary pharmaceuticals, and the creation of bacteriophage-based treatments. A key focus is on preventative medicine, including the research and development of Virus-Like Particle (VLP) vaccines and a nanoparticle-based vaccine for Foot-and-Mouth Disease. In the biomedical sector, Optipharm is advancing xenotransplantation through its 'Medipig' platform for developing xenogeneic organs and tissues. The company also produces transgenic animal models for research and develops cell therapy products using animal stem cells, with a long-term strategy to transition its innovations to human medicine.

Recent filings

Filing Released Lang Actions
주주총회소집결의
AGM Information Classification · 1% confidence The document is a formal notice of a General Meeting of Shareholders (주주총회소집결의) for the company Optipharm. It outlines the date, location, agenda items (such as financial statement approval, director re-election, and compensation limits), and details regarding board attendance. This document serves as a proxy solicitation or notice of meeting materials provided to shareholders to inform them of the upcoming AGM and the items to be voted upon. Given the specific category 'Proxy Solicitation & Information Statement' (PSI) exists for materials requesting votes and providing meeting information, this is the most accurate classification.
2024-03-08 Korean
주주총회소집공고
AGM Information Classification · 1% confidence The document is a 'Notice of General Meeting of Shareholders' (주주총회소집공고) for Optipharm. It contains the meeting agenda, voting procedures, and detailed management information (such as board activities, remuneration, and related party transactions) required by Korean commercial law for such notices. This document is a formal proxy statement/notice sent to shareholders to inform them of the upcoming meeting and provide necessary background information for their votes. In the context of the provided categories, this fits best as a Proxy Solicitation & Information Statement (PSI).
2024-03-08 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 1% confidence The document is a 'Report on Ownership of Specific Securities by Executives and Major Shareholders' (임원ㆍ주요주주 특정증권등 소유상황보고서) filed with the Korean Financial Supervisory Service. It details the share acquisition (insider trading) by a director (Kim Hyun-il) of Optipharm. This falls under the category of Director's Dealing (DIRS).
2024-01-24 Korean
주주명부폐쇄기간또는기준일설정
Regulatory Filings Classification · 1% confidence The document is a formal notice regarding the setting of a record date for the purpose of determining shareholders eligible to vote at the upcoming Annual General Meeting (AGM). It is a short regulatory announcement (under 5,000 characters) that does not contain the full meeting materials or proxy statements, but rather serves as a notification of the procedural step required for the meeting. Given it is a regulatory announcement regarding meeting preparation, it fits best under the RNS category as a general regulatory filing.
2023-12-14 Korean
분기보고서 (2023.09)
Interim / Quarterly Report Classification · 1% confidence The document is a 'Quarterly Report' (분기보고서) for the company 'Optipharm' (주식회사 옵티팜) covering the period from January 1, 2023, to September 30, 2023. It contains detailed financial data, business descriptions, and management information, which aligns with the definition of an Interim/Quarterly Report (IR). 9M 2023
2023-11-13 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 1% confidence The document is titled '임원ㆍ주요주주 특정증권등 소유상황보고서' (Report on Ownership of Specific Securities by Executives and Major Shareholders). It details the share transactions (purchases) made by a director (Kim Hyun-il) of the company Optipharm. This is a standard regulatory filing for insider trading/director dealings in the Korean market.
2023-08-25 Korean

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.